Investors

OvaScience is a global fertility company dedicated to improving treatment options for women around the world.

Copyright Nasdaq. Minimum 15 minutes delayed.

News Release

<< Back
Oct 27, 2016

OvaScience to Host Third Quarter 2016 Financial Results Conference Call

WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 27, 2016-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.m. ET on Thursday, November 3, 2016 to discuss third quarter 2016 financial results and provide a general corporate update.

The live call can be accessed by dialing +1-888-424-8151 for U.S. callers and +1-847-585-4422 for international callers five minutes prior to the start of the call and by providing the passcode 8448237. A live webcast of the conference call will be available online from the Investors section of the Company’s website at www.ovascience.com.

A replay of the conference call will be available from 7:00 p.m. ET on Thursday, November 3, 2016 through 11:59 p.m. ET on Thursday, November 10, 2016, and may be accessed by visiting OvaScience’s website or by dialing +1-888-843-7419 for U.S. callers and +1-630-652-3042 for international callers. The replay access code is 8448237.

About OvaScience
OvaScienceSM (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. The AUGMENTSM treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions. OvaScience is developing the OvaPrimeSM treatment, which could increase a woman’s egg reserve, and the OvaTureSM treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. OvaScience treatments are not available in the U.S. For more information, please visit www.ovascience.com and www.augmenttreatment.com or follow us on Twitter and Facebook.

Source: OvaScience

Media and Investor Contact:
OvaScience
Jennifer Viera, 617-420-8748
jviera@ovascience.com